Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Alexion beat both earnings estimates and sales estimates in the fourth quarter. Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. However, the company relies heavily on Soliris for growth and sales of the same will be impacted increased ALXN1210 trials. Pricing is also projected to hit revenues by 3% in 2018. Shares of the company have underperformed the industry over a year. Among new products, the company redefined its strategy for Kanuma as the drug lagged expectations. Meanwhile, in order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma.”
EQT Midstream Partners (NYSE:EQM) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.
Lloyds Banking Group (NYSE:LYG) was downgraded by analysts at Davy Research from an outperform rating to a neutral rating.
Rexford Industrial Realty (NYSE:REXR) was downgraded by analysts at Capital One Financial Corp. from an overweight rating to an equal weight rating.
Renasant (NASDAQ:RNST) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Renasant Corporation is the parent of Renasant Bank and Renasant Insurance, Inc. “
Revance Therapeutics (NASDAQ:RVNC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “
Scorpio Bulkers (NYSE:SALT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Scorpio Bulkers Inc. is a provider of marine transportation of dry bulk commodities. The company’s vessels consist of Ultramax, Kamsarmax and Capesize. It operates shipyards in Japan, China and Romania. Scorpio Bulkers Inc. is based in MONACO. “
Seacoast Banking Corporation of Florida (NASDAQ:SBCF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Seacoast Banking Corp of Florida is a bank holding company. Seacoast and its subsidiaries offer a full array of deposit accounts and retail banking services, engages in consumer and commercial lending and provides a wide variety of trust and asset management services, as well as securities and annuity products. “
Swisscom (OTCMKTS:SCMWY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Swisscom is Switzerland’s leading telecommunications company. The innovative, customer-focused and strongly-competitive group offers a full range of voice and data communication services on fixed-line and mobile networks. Swisscom offers the complete spectrum of state-of-the-art data services, from leased lines to integrated solutions for corporate customers. “
Scpharmaceuticals (NASDAQ:SCPH) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
Sealed Air (NYSE:SEE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Sealed Air’s fourth-quarter earnings and revenues both improved on a year-over-year basis and also beat the respective Zacks Consensus Estimate. For 2018, Sealed Air projects net sales of approximately $4.75-$4.80 billion and adjusted earnings per share in the range of $2.35-$2.45, a 33% increase at the midpoint. While the Food Care segment saw improvement in North America in 2017, growth rate is anticipated to moderate in 2018. Further, adjusted EBITDA margins are likely be in line with 2017 due to elevated raw material costs. Even though restructuring actions, investments in R&D are projected to drive future growth, it might affect margins in the near term. Moreover, stranded costs following the Diversey divestiture remain a concern. Moreover, Sealed Air has underperformed its industry in the past year.”
Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.